Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis

  • Go, Seong Woo (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kim, Boo Kyeong (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Lee, Sung Hak (Department of Pathology, The Catholic University of Korea College of Medicine) ;
  • Kim, Tae-Jung (Department of Pathology, The Catholic University of Korea College of Medicine) ;
  • Huh, Joo Yeon (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Lee, Jong Min (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Hah, Jick Hwan (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kim, Dong Whi (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Cho, Min Jung (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kim, Tae Wan (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kang, Ji Young (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • Received : 2013.04.29
  • Accepted : 2013.09.16
  • Published : 2013.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.

Keywords

References

  1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
  2. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-4. https://doi.org/10.1038/sj.leu.2404207
  3. Kim TH, Kim BG, Cho SW, Cho SK, Kim HJ, Yuh YJ, et al. Imatinib- mesylate induced interstitial pneumonitis in two CML patients. Tuberc Respir Dis 2011;71:210-5. https://doi.org/10.4046/trd.2011.71.3.210
  4. Lee JW, Kim HJ, Kim KJ, Shin KC, Hong YH, Chung JH, et al. A case of imatinib-mesylate associated hypersensitivity pneumonitis. Tuberc Respir Dis 2005;59:423-6. https://doi.org/10.4046/trd.2005.59.4.423
  5. Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target Oncol 2011;6:235-43. https://doi.org/10.1007/s11523-011-0199-0
  6. Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004;18:645-6. https://doi.org/10.1038/sj.leu.2403251
  7. Snyder LS, Hertz MI, Peterson MS, Harmon KR, Marinelli WA, Henke CA, et al. Acute lung injury: pathogenesis of intraalveolar fibrosis. J Clin Invest 1991;88:663-73. https://doi.org/10.1172/JCI115351
  8. Walsh J, Absher M, Kelley J. Variable expression of plateletderived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol 1993;9:637-44. https://doi.org/10.1165/ajrcmb/9.6.637
  9. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-59. https://doi.org/10.1148/radiographics.20.5.g00se081245
  10. Seki N, Ito A, Watanabe K, Shibakuki R, Seto T, Uematsu K, et al. Irreversible imatinib-induced pneumonitis following longterm imatinib administration. Intern Med 2007;46:1941-2. https://doi.org/10.2169/internalmedicine.46.0542
  11. Delomas T, Darne C, Besson C. Lack of recurrence of imatinib- induced interstitial lung disease with nilotinib. Leuk Lymphoma 2012;53:332-3. https://doi.org/10.3109/10428194.2011.606940

Cited by

  1. Imatinib : Interstitial pneumonitis: case report vol.1521, pp.1, 2013, https://doi.org/10.1007/s40278-014-3890-y
  2. Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas vol.39, pp.11, 2013, https://doi.org/10.1007/s40264-016-0450-9
  3. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia vol.30, pp.8, 2013, https://doi.org/10.1038/leu.2016.104
  4. Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword vol.58, pp.1, 2019, https://doi.org/10.1080/0284186x.2018.1502469